- Home
- LNZA vs SERA Comparison
LNZA vs SERA Comparison
Compare LNZA & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNZA | SERA |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Precision Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.8M | 107.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LNZA | SERA |
|---|---|---|
| Price | $10.37 | $2.38 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 10.0K | ★ 56.8K |
| Earning Date | 03-16-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,876,000.00 | $95,000.00 |
| Revenue This Year | N/A | $25.84 |
| Revenue Next Year | $113.27 | $715.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.06 |
| 52 Week Low | $9.74 | $1.37 |
| 52 Week High | $107.00 | $5.23 |
Technical Indicators
Market Signals| Indicator | LNZA | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 26.70 | 33.01 |
| Support Level | $11.42 | $2.32 |
| Resistance Level | $12.96 | $2.93 |
| Average True Range (ATR) | 0.99 | 0.21 |
| MACD | -0.29 | -0.09 |
| Stochastic Oscillator | 4.72 | 12.77 |
Price Performance
Historical ComparisonAbout LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.